10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

HLA-G antibody - C-terminal region
Rabbit Polyclonal Antibody
Catalog # AI14920

Specification

HLA-G antibody - C-terminal region - Product Information

Application	**WB**
Primary Accession	P17693
Other Accession	NM_002127, NP_002118
Reactivity	**Human, Pig, Bovine**
Predicted	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Calculated MW	**36kDa KDa**

HLA-G antibody - C-terminal region - Additional Information

Gene ID 3135

Alias Symbol	**MHC-G**

Other Names
HLA class I histocompatibility antigen, alpha chain G, HLA G antigen, MHC class I antigen G, HLA-G, HLA-6.0, HLAG

Format
Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage
Add 50 ul of distilled water. Final anti-HLA-G antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions
HLA-G antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

HLA-G antibody - C-terminal region - Protein Information

Name HLA-G {ECO:0000303|PubMed:1570318, ECO:0000312|HGNC:HGNC:4964}

Function
[Isoform 1]: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:<a

href="http://www.uniprot.org/citations/8805247" target="_blank">8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal- fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042, PubMed:29262349). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:16366734, PubMed:19304799, PubMed:23184984, PubMed:29262349). Through interaction with KIR2DL4 receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620).

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane. Early endosome membrane [Isoform 2]: Cell membrane; Single-pass type I membrane protein [Isoform 4]: Cell membrane; Single-pass type I membrane protein [Isoform 6]: Secreted Cell projection, filopodium membrane. Note=HLA-G trogocytosis from extravillous trophoblast's filopodia occurs in the majority of decidual NK cells.

Tissue Location

Expressed in adult eye (PubMed:1570318). Expressed in immune cell subsets including monocytes, myeloid and plasmacytoid dendritic cells and regulatory T cells (Tr1)(at protein level) (PubMed:20448110). Secreted by follicular dendritic cell and follicular helper T cells (PubMed:24453251) [Isoform 7]: Expressed in placenta, amniotic membrane, skin, cord blood and peripheral blood mononuclear cells

HLA-G antibody - C-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

HLA-G antibody - C-terminal region - Images



WB Suggested Anti-HLA-G Antibody Titration: 1.0 µg/ml
Positive Control: RPMI-8226 Whole Cell.HLA-G is strongly supported by BioGPS gene expression data to be expressed in RPMI-8226

HLA-G antibody - C-terminal region - References

Shukla H.,et al.Nucleic Acids Res. 18:2189-2189(1990).
Geraghty D.E.,et al.Proc. Natl. Acad. Sci. U.S.A. 84:9145-9149(1987).
Ishitani A.,et al.Submitted (APR-1992) to the EMBL/GenBank/DDBJ databases.
Hampe A.,et al.DNA Seq. 10:263-299(1999).
Shiina S.,et al.Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.